Germany’s HTA Process May Ease After Scientific Associations’ Input
This article was originally published in The Pink Sheet Daily
Executive Summary
This year’s parliamentary elections in Germany may get more heated after five scientific associations sent a letter to the country’s senior reimbursement authorities calling for increased transparency and better use of comparators in selecting new drugs.
You may also be interested in...
European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation
German health insurers run a cash surplus in the first quarter; Celesio CEO dismissed; Bayer celebrates 150 years; Spain wants to evaluate value for drug pricing; France's drug spend declines in 2012, and more.
European Notebook: AstraZeneca Snuggles Up To Potential Partners In New Cambridge HQ, Viagra Patents Expire In Europe
AstraZeneca's new HQ is to cornerstone a growing U.K. cluster of clinical and research assets; the EU and U.S. start talks on what could be the world's largest free trade agreement; Viagra patent expiry provides a lift for European generic companies; European wholesalers support the liquidity of European health care markets; new pricing system for generics in Ireland.
Germany's Health Reform Law Stumbles Through Parliament
Measure will curtail manufacturer latitude on drug pricing, especially for new drugs not shown to have added benefit over existing products.